Background: To identify risk factors of recurrence in a large series of patients with breast cancer who underwent a nipple-sparing mastectomy (NSM).
introduction
A breast conservative treatment is proposed in at least twothird of patients with diagnosis of primary breast cancer [1, 2] . Total mastectomy remains indicated in case of large or multicentric tumor. In the recent years, many publications proved that skin-sparing mastectomy (SSM) provides a good opportunity to improve the results of breast reconstruction without modifying the safety of the surgery in stage I and II [3] . More recently, to decrease the psychological impact of mutilation, the conservation of the nipple areola complex (NAC) has been proposed [4, 5] . The conservation of the NAC helps the patient to feel less mutilated in preserving an important part of her breast identity [6] . Preservation of NAC is accused to increase the risk of local recurrences in the retroareolar glandular tissue. A large set of publications has been dedicated to the incidence of nipple involvement by the tumor to select nipple-sparing mastectomy (NSM) indications [7] [8] [9] . The characteristics associated with nipple involvement are tumor size, histological type, distance from the nipple, multifocality, and involved nodes. However, these criteria are either not available before surgery or not reliable because of the size of the studies and the difference of methodology [10] . The distance from the tumor to the nipple is proposed as one of the best criteria to select the patient. However, in most cases, the margins of the cancer are difficult to evaluate clinically. In 2008, Voltura et al. [11] proposed the selection of patients for NSM on the following criteria: tumor size ≤4.5 cm, tumor distance from the areola ≥2.5 cm or ≥4 cm from the nipple center, no gross involvement of the NAC, including bloody discharge or Paget's disease. In large nodules as well as in multifocal tumor, the most important criteria appears to be the NAC infiltration by the tumor. Radiological distance (mammogram or magnetic resonance imaging) has been advocated by Loewen et al. [12] and Yamashiro et al. [13] as a better predictor of NAC involvement. They found a risk of involvement when the distance was <4.96 cm with a sensitivity of 82% and a negative predictive value of 97%. Therefore, if the decision is based on the clinical distance, it is recommended to limit NSM indications to tumors located clinically grossly at 5 cm from the nipple. At the European Institute of Oncology (IEO), we started to perform NSM in 2002 [14, 15] . More than 2000 NSM have been carried out for invasive and in situ cancers. Our protocol includes an electron intraoperative treatment (ELIOT) on the NAC to decrease the risk of local recurrences (LR) in the retroareolar glandular tissue preserved to keep the areola blood supply [16] . Psychological benefit and quality of the cosmetic results of the NSM have been widely reported in the recent literature [17, 18] . But the cancer risk of NSM in breast cancer patients remains an important debate and the role of the ELIOT is still not recognized by most cancer teams. Based on our experience of NSM at the IEO, we analyzed our cancer results and the risk factors of recurrences in a series of 934 NSM operated between March 2002 and December 2007.
patients and methods
From March 2002 to December 2007, 934 women underwent an NSM at the IEO: 772 patients with invasive carcinoma (group A) and 162 with intraepithelial neoplasm (group B). The selection of patients was based on the clinical and radiological evaluation: tumor located outside of the areola area, no nipple retraction, no blood discharge from the nipple, no inflammatory signs, no previous irradiation and no micro calcifications and frozen retroareolar section negative for carcinoma. In our series, patients with bilateral cancer, benign disease, preoperative radio-or chemotherapy were not included. Clinical lymphadenopathy was not a contraindication. Sentinel node frozen section was carried out to decide the surgical axillary treatment. An informed consent was undersigned by the patients before the operation. Subcutaneous mastectomy was carried out by the cancer team, followed immediately by intraoperative radiotherapy on the nipple areola and immediate breast reconstruction by the plastic surgery team. The areola irradiation was postponed or canceled when the blood supply of the NAC after the subcutaneous mastectomy was critical.
radiosurgical technique
The subcutaneous mastectomy is carried out through a cutaneous incision drawn usually above the tumor site, mostly radial or peri-or para-areolar when the tumor is located in the superior quadrants. The glandular tissue is dissected underneath the dermis leaving a thin layer of 3-5 mm fat tissue to preserve the sub-dermal vessels. The gland is removed down to the pectoralis fascia, which was preserved in around half of the patients. The specimen is sent to the pathologist with stitches to mark the retroareolar area and on the axillary tail of the gland. A separate slice of glandular tissue taken from the retroareolar area is sent to the pathologist for frozen examination. The radiotherapy team is called upon to do the ELIOT when the frozen examination was proved negative for cancer infiltration. A oneshot electron beam is delivered on the NAC by a dedicated linear accelerator. The single dose of 16 Gy has been calculated according to the linear-quadratic model (with a value of alpha/beta ratio of 4 for breast cancer) to be equivalent to a fractionated dose ranging from 40 to 45 Gy. The clinical target volume, fully encompassed by the collimator, is the diameter of the areola plus 1 cm margin around. The entire target is included in the 90% isodose [14, 15, [19] [20] [21] . Then the plastic surgeon is called upon immediately to reconstruct the breast using one of the techniques adapted to the particular case: definitive implant, expander or musculo-cutaneous flaps. NAC irradiation was postponed or canceled when the blood supply after the subcutaneous mastectomy was critical.
adjuvant treatment
The adjuvant medical treatment was indicated according to hostage and biological features of disease. Secondary radiotherapy on the thoracic area was carried out in case of extensive axillary involvement. Patients were followed regularly every 6 months up to 3 years and then every year. They were recalled when lost for follow-up.
statistical methods
Survival end points were breast-related recurrences, LR in the breast and NAC recurrences. In group A, we considered only invasive events, while in group B, we considered both intraepithelial and invasive events. The cumulative incidences were estimated in a competing risk framework [22] . For the analysis of breast-related recurrences, we treated deaths from causes other than breast cancer, other primaries and contralateral breast cancers as competing events. For the analysis of LR recurrences, we treated distant metastases, death from any cause, other primaries and contralateral breast cancer as competing events. For the analysis of NAC recurrences, we treated early removals of the NAC for necrosis, distant metastases, and death from any cause, other primaries and contralateral breast cancer as competing events. The Gray test was used to assess the significance of differences in events across subgroups. Differences with P < 0.10 were considered statistically significant in the univariate analysis and were analyzed by multivariate Cox proportional hazard model. Analyses were carried out with the SAS software version 9.2 (SAS Institute, Cary, NC) and R software version 2.12.2 (available at www.r-project.org). All tests were two-sided. Table 1 (group A) and Table 2 (group B) . In group A, we observed 28 LR (3.6%) in the breast at 5-year cumulative incidence and 6 LR (0.8%) on the NAC. In group B, we observed nine LR (4.9%) in the breast and five LR (2.9%) on the NAC. In group A, 5-year cumulative incidence of breast-related events was 14.7% and overall survival was 95.5% [confidence interval (CI) 93.2% to 97.1%]. The characteristics of the 11 patients with NAC recurrence are described in Table 3 . Among the LR on the NAC, we observed seven Paget of the nipple associated with ductal carcinoma in situ (DCIS) in the underlying ducts and four LR with invasive carcinoma. The 11 recurrences on the NAC were removed and patients are free of disease after a median follow up of 33 months. In 70 patients with negative intraoperative frozen section, submitted to ELIOT, the final definitive histology was positive. In agreement with the patients their NAC was preserved despite the lack of free margin at the final histological examination. Such decision was encouraged by the efficacy of the ELIOT observed in our previous experience on the tumor bed in breast-conserving surgery [16] . No LR was observed in these 76 cases.
At the multivariable analysis of all the breast-related recurrences, number of positive lymph nodes, histotype and Ki-67 index were significant prognostic factors. Histotype and Ki-67 index were independent risk factors for the locoregional recurrences after invasive cancer. Tumor size, receptor status, HER2/neu, grade and Ki-67 were associated with the risk of NAC recurrence after an invasive tumor.
original articles Annals of Oncology
No more multivariable analyses were carried out in group B due to the sparse number of events. In univariate analysis, age, estrogen receptor (ER) status, HER2/neu, grade and Ki-67 index were associated with the locoregional recurrences after intraepithelial lesion. In addition to receptor status, HER2/neu, grade and Ki-67 index, also age and retroareolar margins emerged as prognostic factors for the NAC recurrence after intraepithelial lesion. original articles Annals of Oncology breast cancer-specific death [24] . In our study, as predicted by the results of the literature, for invasive tumors, the risk of all breast-related invasive recurrence is related to the tumor size, the number of positive nodes, the histotype, the grade and the biological features of disease (HER2/neu, Ki-67, vascular invasion) [25] . The LR rate observed in our series 3.6% and 4.9% in groups A and B, respectively, is consistent with the results of the total mastectomy reported by Fisher et al.
[2]. Horiguchi et al. [26] found a LR rate different comparing radical mastectomy to subcutaneous mastectomy 1.3% versus 3.8% at 5 years. But they did not observe any difference for the survival rate [25] . Newman et al.
[3], Vaughan et al. [27] and Medina-Franco et al. [28] reported a 6.2% LR at 5 years, 5.3% LR at 5 years and 4.5% LR at 8 years, respectively, after SSM. Gerber et al. [24] did not observe any difference between the LR rate of modified mastectomy, SSM and NSM 11.5% versus 10.4% versus 11.7%, respectively, at 8.4 years. In our series of invasive cancers (Table 1) , the risk factors of LR in the breast were the tumor grade and HER2/neu. But when looking specifically to the recurrences on the NAC, the risk factors were the extensive in situ component, hormonal receptors and biomarkers. Lari and Kuerer [29] underlined in a multivariate analysis that the phenotype HER2+, ER−, Ki67+ was a strong predictor of DCIS recurrence. In our study, the luminal A is the only group with no increasing risk of LR in the breast including for LR on the NAC. Gabos et al. [30] showed in their study the role of the phenotypes HR(hormonal receptor)+/HER2+, HR−/HER2+ and triple negative subtypes were associated with increased risk of LR in univariate analysis. In a multivariate analysis, tumor size and positive lymph node status were associated with increased risk of LR. We did not observe the same results in our series. The LR rate in the breast in the group of 162 intraepithelial neoplasia (group B, Table 2 ) is slightly higher than for the invasive tumors: 4.9% versus 3.6%. These results are consistent with the results reported by Kim et al. [31] in a review article on the noninvasive cancer showing an LR rate of 0%-7.7% per 5 years. In our series of noninvasive cancer, age, ERs, grade, HER2/neu and Ki67 are risk factors for breast LR. For the recurrences on the NAC, age, retroareolar margins, ER more than progesterone receptor (PgR), grade, HER2/neu and Ki 67 are significant risk factors (Table 2 ). Lari and Kuerer [29] conclude in their systematic review that it is difficult to elucidate the prognostic importance of the biomarkers in the LR rate of in situ carcinomas because of heterogenous treatments and conflicting results of the different studies and small number of patients. However, they underline the association between ER-DCIS and risk of LR. Patients with LR were likely to be ER negative, HER2/neu and Ki 67 positive. Conversely, only 2 of 13 studies reviewed revealed a significant correlation between progesterone receptor and LR. Six out of nine studies revealed a correlation between Ki67 and LR; the three others did not show any correlation. Finally, Lari and Kuerer [29] found only four studies demonstrating a correlation between the HER2 level and the risk of LR. Fortyeight patients did not undergo intra-or postoperative radiotherapy mainly because of the poor blood supply of the NAC after the subcutaneous mastectomy. Absence of ELIOT was not a risk factor for LR. But the discrepancy between the groups with or without ELIOT does not allow drawing conclusions. In our study, retroareolar margins do not appear to be a risk factor of LR on the NAC. When looking at the characteristics of the NAC recurrences, we observe that 10 of 11 are either intraepithelial carcinomas or invasive carcinomas associated with extensive in situ component. The presence of pure in situ lesion or invasive carcinoma with extensive intraductal seems to increase the risk of NAC recurrence. Scheiden et al. [32] reported high accuracy of frozen section examination in breast lesion, particularly for retroareolar tissue. Lohsiriwat et al. [33] revealed 93.5% accuracy, 93.8% positive predictive value and 93.3% negative predictive value. However, when we focus on the group of 70 patients with positive definitive retroareolar histology and received ELIOT (56 in group A and 14 in group B), we observe that 54 of these margins were in situ and 16 were invasive carcinoma. Such results confirm the high difficulty to get a reliable extemporaneous examination in case of in situ lesion. No LR was observed in this group. Such result plays in favor of ELIOT efficacy.
conclusions
The LR rate in the breast, distant recurrence and death rate of our NSM are consistent with the results of the literature after radical mastectomy or SSM. Our results confirm the validity of our protocol of NSM selection based on the retroareolar extemporaneous histology. However, our study shed the light on the role of age, grading, hormonal receptors and biological markers particularly in intraepithelial neoplasia. In our series, only seven women with intraepithelial neoplasia were ≤44 years and had ER <5 and PgR <5. Four of them (57%) had a NAC recurrence suggesting that in patients <45 years with poorly hormone responsive tumor, NSM could be removed from NSM indications. Systematic preoperative histology could be the best solution to get detailed histology, hormonal and biological results in order to reduce the LR risk while selecting the indications of NSM on the risk factors individualized in our study. Although our results do not bring about any objective confirmation that ELIOT decreases the risk of LRs on the NAC, the lack of LR in the group of false-negative retroareolar frozen examination may be considered as an argument in favor of the efficacy of ELIOT.
